Rodabe N Amaria

Trials

Studies that name Rodabe N Amaria as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07511036 · PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

  M.D. Anderson Cancer Center · not yet recruiting · Melanoma · principal investigator
• Ph1/Ph2
  NCT06598371 · A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

  M.D. Anderson Cancer Center · recruiting · Select Advanced Solid Tumors · principal investigator
• Ph1/Ph2
  NCT06237881 · A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

  M.D. Anderson Cancer Center · active not recruiting · Advanced Solid Tumor, Melanoma, Lung Neoplasms · principal investigator
• Ph1
  NCT05470283 · Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

  M.D. Anderson Cancer Center · active not recruiting · Tumor, Metastatic Melanoma, Melanoma · principal investigator
• Ph2
  NCT04310397 · Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

  M.D. Anderson Cancer Center · terminated · Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8 · principal investigator
• Ph2
  NCT02519322 · Neoadjuvant and Adjuvant Checkpoint Blockade

  M.D. Anderson Cancer Center · completed · Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma · principal investigator
• Ph2
  NCT02500576 · Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

  M.D. Anderson Cancer Center · completed · Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 · principal investigator
• Ph2
  NCT02231775 · Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

  M.D. Anderson Cancer Center · active not recruiting · Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 · principal investigator
• Ph1/Ph2
  NCT02225366 · Intratumoral Injections of LL37 for Melanoma

  M.D. Anderson Cancer Center · completed · Melanoma · principal investigator
• Ph1
  NCT01955460 · Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

  M.D. Anderson Cancer Center · active not recruiting · Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 · principal investigator
• Ph1/Ph2
  NCT01740557 · Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

  M.D. Anderson Cancer Center · completed · Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 · principal investigator
• Ph1
  NCT01603212 · Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

  M.D. Anderson Cancer Center · completed · Melanoma · principal investigator
• Ph1
  NCT01409174 · IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma

  M.D. Anderson Cancer Center · terminated · Melanoma · principal investigator
• Ph1
  NCT01067066 · A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

  M.D. Anderson Cancer Center · terminated · Melanoma · study chair
• Ph1
  NCT01039844 · Study of Weekly LOC-paclitaxel Injection for Melanoma

  M.D. Anderson Cancer Center · terminated · Melanoma · principal investigator
• Ph2
  NCT00338377 · Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

  M.D. Anderson Cancer Center · active not recruiting · Melanoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
  P50CA093459 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ELIZABETH A GRIMM · fiscal years 2004 to 2014
  Named on NCT02225366
• Transduction of T cells to improve migration to tumor
  R01CA116206 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PATRICK HWU · fiscal years 2005 to 2014
  Named on NCT01740557
• The role of the PI3K pathway in immune resistance
  R01CA187076 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, PATRICK HWU · fiscal years 2014 to 2018
  Named on NCT00338377